Zalicus Inc (ZLCS) 1.18 $ZLCS
Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. to Serve on EPIRUS Board of Directors
Business Wire - Tue Jul 15, 10:49AM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced that Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. will serve on its board of directors. The board, which was reconstituted today following the company's merger with Zalicus Inc. (Zalicus, NASDAQ: ZLCS), also includes Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotian Fu.
EPIRUS and Zalicus Complete Merger - Combined Company Will Trade as EPIRUS Biopharmaceuticals, Inc. (NASDAQ: EPRS)
Business Wire - Tue Jul 15, 10:47AM CDT
--EPIRUS reconstitutes Board of Directors to include Mark H.N. Corrigan, M.D., Julie H. McHugh, William Hunter, M.D., Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotian Fu
Zalicus and Epirus Agree Zalicus Stockholders to Own 19% of Combined Company Post-Merger
Business Wire - Wed Jun 25, 7:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS) ("Zalicus"
, and Epirus Biopharmaceuticals, Inc. ("Epirus" agreed today that Zalicus stockholders will own 19% of the combined company post-merger. Pursuant to its merger agreement with Epirus Biopharmaceuticals, Inc., the percentage of the combined company that Zalicus stockholders will own as of the closing of the merger was subject to adjustment at the closing based on the level of Zalicus' net cash as of a determination date prior to the closing. Based on Zalicus' current level of net cash, both companies have agreed that stockholders of Zalicus will own approximately 19% of the combined company and current Epirus equityholders will own approximately 81% of the Company following the merger.
Anabios Licenses Sodium Channel Blocking Pain Therapeutic Portfolio from Zalicus
PRWeb - Thu Jun 19, 3:16AM CDT
AnaBios Corporation announced today the licensing of a portfolio of novel preclinical, sodium channel blocking pain therapeutics from Zalicus Inc. The agreement is aimed at accelerating the successful development of new selective sodium channel blockers by employing AnaBios' proprietary Phase X™ technology. Under the terms of the agreement, AnaBios acquires an exclusive license for all development and commercialization rights related to Zalicus' Nav1.7 portfolio of compounds, having a projected commercial market of at least $1.5B annually. In addition, Zalicus will be eligible for future clinical and regulatory milestone payments from AnaBios and the two companies will share in royalty payments based upon any potential future product sales.
Zalicus Licenses Sodium Channel Pain Modulation Program
Business Wire - Wed Jun 18, 7:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has licensed its Sodium Channel Modulator program, including intellectual property and related pipeline assets, to AnaBios Corporation in exchange for clinical milestone payments and royalties on potential future sales. Under the terms of the agreement Zalicus will be eligible to receive up to $17.2 million in clinical and regulatory milestone payments and up to 12% of net sales on any future products resulting from this license.
Sales, Clinical Hold Removal, Trial Initiations, and Committee Recommendations - Analyst Notes on Geron, Zalicus, Northwest Biotherapeutics, Progenics and TG Therapeutics
PR Newswire - Tue Jun 17, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Geron Corporation (NASDAQ: GERN), Zalicus Inc. (NASDAQ: ZLCS), Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and TG Therapeutics, Inc. (NASDAQ: TGTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3775-100free.
Short Squeeze Starting in Zalicus (ZLCS) According to WealthMakers.com Report
M2 - Fri Jun 13, 6:54AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a research report on Zalicus (NASDAQ: ZLCS). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $1.49 and the projected fundamental valuation of $6.60.
Why Zalicus (ZLCS) Stock Is Surging Today
at The Street - Thu Jun 12, 10:10AM CDT
Zalicus (ZLCS) surged Thursday after Epirus Switzerland announced clinical data from a Phase 3 study of BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis.
Zalicus to Present at AACR 2014 Annual Meeting
Business Wire - Tue Apr 01, 7:30AM CDT
Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that a poster developed in collaboration with colleagues from Eisai Inc. and a podium presentation with collaborators from Sanofi will be given at the American Association for Cancer Research (AACR) 2014 Annual Meeting which takes place April 5-9, 2014 in San Diego, CA. These preclinical data, which were generated in separate studies by leveraging the Zalicus combination High-throughput screening (cHTS(TM)) technology platform, demonstrate the potential to identify (or highlight) synergistic activity of the Eisai nontaxane eribulin and the Sanofi antibody drug conjugate SAR3419, through drug combinations.
Zalicus Reports Financial Results for the Fourth Quarter and Year-End 2013
Business Wire - Thu Mar 13, 6:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the fourth quarter and year ended December 31, 2013.
Canadian Forex Review: C$ Strengthens
Commodity News Service Canada - Commodity News Service Canada, Inc. - Wed Feb 12, 3:44PM CST
The Canadian dollar strengthened against the US dollar on Wednesday amid positive Chinese trade data, analysts said.
Hot Stock: Zalicus, Shares Gain 11.5% (ZLCS)
Comtex SmarTrend(R) - Wed Jan 22, 10:11AM CST
Zalicus (NASDAQ:ZLCS) is one of today's best performing low-priced stocks, up 11.5% to $2.14 on 3.1x average daily volume. Thus far today, Zalicus has traded 4.3 million shares, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (25.9% to the Dow's -0.4%) and outperformed the S&P 500 (25.9% to the S&P's -0.1%) during today's trading.
3 Stocks Under $10 in Breakout Territory
at The Street - Wed Jan 22, 6:00AM CST
These under-$10 stocks are within range of triggering major breakout trades.
Traders Get Bullish on Shares of Zalicus, Shares Up 8.6% (ZLCS)
Comtex SmarTrend(R) - Fri Jan 17, 12:47PM CST
Zalicus (NASDAQ:ZLCS) is one of today's best performing low-priced stocks, up 8.6% to $1.76 on 1.1x average daily volume. Zalicus has traded 1.5 million shares thus far today, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (8.6% to the Dow's 0.3%) and outperformed the S&P 500 (8.6% to the S&P's -0.2%) during today's trading.
Preliminary Results, Conferences, Stock Price Movements, and Acquisitions - Research Report on Community Health, ArthroCare, NuPathe, Zalicus, and Neogen
PR Newswire - Mon Jan 13, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
5 Stocks Under $10 Set to Soar
at The Street - Fri Jan 10, 6:00AM CST
These under-$10 stocks look ready to trade higher from current levels.
Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better
at The Street - Thu Jan 09, 10:13AM CST
The biotech sector has jumped off to a strong start to 2014, with today's blockbuster move in Intercept Pharma offering a big assist. I know it's ridiculously early to make any sort of definitive judgment, but I wondered how the first days of biotech...
5 Stocks Poised for Breakouts
at The Street - Fri Jan 03, 2:19PM CST
These stocks look ready to break out and trade higher from current levels.
Stock to Watch: Zalicus Up 14.3% (ZLCS)
Comtex SmarTrend(R) - Fri Jan 03, 11:42AM CST
Zalicus (NASDAQ:ZLCS) is one of today's best performing low-priced stocks, up 14.3% to $1.28 on 1.5x average daily volume. Thus far today, Zalicus has traded 2.1 million shares, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (14.3% to the Dow's 0.2%) and outperformed the S&P 500 (14.3% to the S&P's -0.0%) during today's trading.
Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. to Serve on EPIRUS Board of Directors
Business Wire - Tue Jul 15, 10:49AM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced that Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. will serve on its board of directors. The board, which was reconstituted today following the company's merger with Zalicus Inc. (Zalicus, NASDAQ: ZLCS), also includes Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotian Fu.
EPIRUS and Zalicus Complete Merger - Combined Company Will Trade as EPIRUS Biopharmaceuticals, Inc. (NASDAQ: EPRS)
Business Wire - Tue Jul 15, 10:47AM CDT
--EPIRUS reconstitutes Board of Directors to include Mark H.N. Corrigan, M.D., Julie H. McHugh, William Hunter, M.D., Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotian Fu
Zalicus and Epirus Agree Zalicus Stockholders to Own 19% of Combined Company Post-Merger
Business Wire - Wed Jun 25, 7:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS) ("Zalicus"
, and Epirus Biopharmaceuticals, Inc. ("Epirus" agreed today that Zalicus stockholders will own 19% of the combined company post-merger. Pursuant to its merger agreement with Epirus Biopharmaceuticals, Inc., the percentage of the combined company that Zalicus stockholders will own as of the closing of the merger was subject to adjustment at the closing based on the level of Zalicus' net cash as of a determination date prior to the closing. Based on Zalicus' current level of net cash, both companies have agreed that stockholders of Zalicus will own approximately 19% of the combined company and current Epirus equityholders will own approximately 81% of the Company following the merger. Anabios Licenses Sodium Channel Blocking Pain Therapeutic Portfolio from Zalicus
PRWeb - Thu Jun 19, 3:16AM CDT
AnaBios Corporation announced today the licensing of a portfolio of novel preclinical, sodium channel blocking pain therapeutics from Zalicus Inc. The agreement is aimed at accelerating the successful development of new selective sodium channel blockers by employing AnaBios' proprietary Phase X™ technology. Under the terms of the agreement, AnaBios acquires an exclusive license for all development and commercialization rights related to Zalicus' Nav1.7 portfolio of compounds, having a projected commercial market of at least $1.5B annually. In addition, Zalicus will be eligible for future clinical and regulatory milestone payments from AnaBios and the two companies will share in royalty payments based upon any potential future product sales.
Zalicus Licenses Sodium Channel Pain Modulation Program
Business Wire - Wed Jun 18, 7:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has licensed its Sodium Channel Modulator program, including intellectual property and related pipeline assets, to AnaBios Corporation in exchange for clinical milestone payments and royalties on potential future sales. Under the terms of the agreement Zalicus will be eligible to receive up to $17.2 million in clinical and regulatory milestone payments and up to 12% of net sales on any future products resulting from this license.
Sales, Clinical Hold Removal, Trial Initiations, and Committee Recommendations - Analyst Notes on Geron, Zalicus, Northwest Biotherapeutics, Progenics and TG Therapeutics
PR Newswire - Tue Jun 17, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Geron Corporation (NASDAQ: GERN), Zalicus Inc. (NASDAQ: ZLCS), Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and TG Therapeutics, Inc. (NASDAQ: TGTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3775-100free.
Short Squeeze Starting in Zalicus (ZLCS) According to WealthMakers.com Report
M2 - Fri Jun 13, 6:54AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a research report on Zalicus (NASDAQ: ZLCS). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $1.49 and the projected fundamental valuation of $6.60.
Why Zalicus (ZLCS) Stock Is Surging Today
at The Street - Thu Jun 12, 10:10AM CDT
Zalicus (ZLCS) surged Thursday after Epirus Switzerland announced clinical data from a Phase 3 study of BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis.
Zalicus to Present at AACR 2014 Annual Meeting
Business Wire - Tue Apr 01, 7:30AM CDT
Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that a poster developed in collaboration with colleagues from Eisai Inc. and a podium presentation with collaborators from Sanofi will be given at the American Association for Cancer Research (AACR) 2014 Annual Meeting which takes place April 5-9, 2014 in San Diego, CA. These preclinical data, which were generated in separate studies by leveraging the Zalicus combination High-throughput screening (cHTS(TM)) technology platform, demonstrate the potential to identify (or highlight) synergistic activity of the Eisai nontaxane eribulin and the Sanofi antibody drug conjugate SAR3419, through drug combinations.
Zalicus Reports Financial Results for the Fourth Quarter and Year-End 2013
Business Wire - Thu Mar 13, 6:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the fourth quarter and year ended December 31, 2013.
Canadian Forex Review: C$ Strengthens
Commodity News Service Canada - Commodity News Service Canada, Inc. - Wed Feb 12, 3:44PM CST
The Canadian dollar strengthened against the US dollar on Wednesday amid positive Chinese trade data, analysts said.
Hot Stock: Zalicus, Shares Gain 11.5% (ZLCS)
Comtex SmarTrend(R) - Wed Jan 22, 10:11AM CST
Zalicus (NASDAQ:ZLCS) is one of today's best performing low-priced stocks, up 11.5% to $2.14 on 3.1x average daily volume. Thus far today, Zalicus has traded 4.3 million shares, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (25.9% to the Dow's -0.4%) and outperformed the S&P 500 (25.9% to the S&P's -0.1%) during today's trading.
3 Stocks Under $10 in Breakout Territory
at The Street - Wed Jan 22, 6:00AM CST
These under-$10 stocks are within range of triggering major breakout trades.
Traders Get Bullish on Shares of Zalicus, Shares Up 8.6% (ZLCS)
Comtex SmarTrend(R) - Fri Jan 17, 12:47PM CST
Zalicus (NASDAQ:ZLCS) is one of today's best performing low-priced stocks, up 8.6% to $1.76 on 1.1x average daily volume. Zalicus has traded 1.5 million shares thus far today, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (8.6% to the Dow's 0.3%) and outperformed the S&P 500 (8.6% to the S&P's -0.2%) during today's trading.
Preliminary Results, Conferences, Stock Price Movements, and Acquisitions - Research Report on Community Health, ArthroCare, NuPathe, Zalicus, and Neogen
PR Newswire - Mon Jan 13, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
5 Stocks Under $10 Set to Soar
at The Street - Fri Jan 10, 6:00AM CST
These under-$10 stocks look ready to trade higher from current levels.
Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better
at The Street - Thu Jan 09, 10:13AM CST
The biotech sector has jumped off to a strong start to 2014, with today's blockbuster move in Intercept Pharma offering a big assist. I know it's ridiculously early to make any sort of definitive judgment, but I wondered how the first days of biotech...
5 Stocks Poised for Breakouts
at The Street - Fri Jan 03, 2:19PM CST
These stocks look ready to break out and trade higher from current levels.
Stock to Watch: Zalicus Up 14.3% (ZLCS)
Comtex SmarTrend(R) - Fri Jan 03, 11:42AM CST
Zalicus (NASDAQ:ZLCS) is one of today's best performing low-priced stocks, up 14.3% to $1.28 on 1.5x average daily volume. Thus far today, Zalicus has traded 2.1 million shares, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (14.3% to the Dow's 0.2%) and outperformed the S&P 500 (14.3% to the S&P's -0.0%) during today's trading.
